Patients
corneal lesions, ocular trauma, Johnson & Johnson Vision, glaucoma, ocular surface disease, microphthalmia
CHRONIC UVEITIS, IOL, BILATERAL AGE-RELATED CATARACT, ASTIGMATISM, PATHOLOGICAL MYOPIA, RETINAL DISEASES, MAY, WEST, LENS, GLAUCOMA, OPTIC NERVE DISEASES, COMPLICATIONS
This study is a prospective cohort focusing on patients with bilateral age-related cataract who were scheduled for phacoemulsification and intraocular lens implantation from May 2022 to June 2023 in Dept. of ophthalmology in West China Hospital of Sichuan University. All patients were offered participation during this period and 9 patients withdrew before the end of the study due to geographical inconvenience. The study was approved by the medical ethics committee of West China Hospital and conducted in accordance with the principles of the Declaration of Helsinki. Patients were divided into three groups based on their own vision requirements at different distances and their choice of IOLs. According to the preoperative target refraction and the actual refractive result at 3 months after operation, patients with both eyes implanted with Symfony IOL were divided into Micro monovision group (difference of spherical equivalent refraction of both eyes was between − 0.5D and − 1.0D) and Non-micro monovision group (difference of spherical equivalent refraction of both eyes was <0.5D. Patients implanted with Symfony IOL in the dominant eye and a bifocal IOL (ZMB00, Johnson & Johnson Vision, Santa Ana, USA) in the nondominant eye were included in the Mixed group.We recruited patients with bilateral age-related cataract who wished to be free of glasses. Patients were included if they were over 18 years of age, had a postoperative residual corneal astigmatism ≤ 1.0D, a natural pupil diameter between 3.0 and 5.5 mm in the dark room, and an angle κ less than 0.5 mm or half the diameter of the central refractive optical zone of the IOL. Patients with any of the following conditions were excluded from the study: microphthalmia, pathological myopia, obvious pupil abnormalities, severe corneal lesions, chronic uveitis, glaucoma, progressive retinal diseases, severe optic nerve diseases, history of ocular trauma or ocular surgery which may influence the calculation of IOL power or postoperative vision, professional drivers and frequent nighttime drivers, severe ocular surface disease, and patients incapable of cooperating with exams or follow-up. All patients must sign a written informed consent form and are informed of the surgical and follow-up plan, possible complications and precautions.